Continued strong momentum for ProFound AI™ iCAD’s proprietary cancer detection AI technology

 Conference call today at 8:30 a.m. ET

NASHUA, N.H. – October 30, 2019 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions today reported its financial and operating results for the three and nine... Continue reading

With 1 in 8 women at risk of developing breast cancer in her lifetime[i], it’s important to know your personal risk and get screened regularly. Breast cancer screening has improved significantly in recent years, making it more important than ever for women to know about the latest advancements that can help doctors find cancers earlier, when they may be more easily treated. Before you book your next mammogram, talk to your doctor about your personal risks and what option is best for you.

Continue reading

NASHUA, N.H., Oct. 24, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter and nine-months ended September 30, 2019, before the market open, and host a conference call at 8:30am Eastern Time on Wednesday, October 30, 2019.

Wednesday, October 30th @ 8:30am ET

Domestic:

877-407-0784

iCAD to Showcase Entire ProFound AI Platform, including its Solutions for 2D Mammography and Digital Breast Tomosynthesis in Paris at Medical Conference

NASHUA, N.H. and PARIS – October 7, 2019 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the full ProFound AI™ platform will be featured in the iCAD exhibition booth (#226A) at the Journées Francophones de Rad... Continue reading

Company to exhibit ProFound AI for 2D and 3D Mammography in Europe

Nashua, N.H. and Budapest, Hungary – October 1, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will exhibit the ProFound AI™ platform, including ProFound AI™ for 2D Mammography and ProFound AI™ for Digital Breast Tomosynthesis (DBT) in the iCAD exhibition booth (#13) at the Eu... Continue reading

Enhanced x-ray source technology and full suite of Xoft eBx applicators to be showcased, including those for emerging applications in prostate, brain, and rectal cancers

NASHUA, N.H. and CHICAGO – September 16, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase its latest advancements for the Xoft® Axxent® Electronic... Continue reading

iCAD, Inc. recently received the “Best New Radiology Solution” Award for the ProFound AI™ platform in the 2019 MedTech Breakthrough Awards Program. The program recognizes the top companies and solutions in the global health and medical technology industries; this year, over 3,500 nominations were considered from more than 15 countries around the world.

ProFound AI for Digital Breast Tomosynthesis (DBT) is the first and only FDA-cleared 3D tomosynthesis technology using artificial intelligence (AI). The technology was designed to ad... Continue reading

First and Only FDA-Cleared Digital Breast Tomosynthesis Software with Artificial Intelligence Clinically Proven to Enhance Breast Cancer Screening, Reduce False Positives and Slash Reading Time for Radiologists in Half

Nashua, N.H. – September 10, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the results of its reader study for ProFound AI™ fo... Continue reading

First and Only FDA-Cleared Artificial Intelligence Solution Supporting Breast Cancer Detection in 3D Tomosynthesis Recognized by Annual Awards Program

NASHUA, N.H – September 4, 2019 – iCAD, Inc. (“iCAD”) (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced MedTechBreakthrough, an independent organization that recognizes the top companies and solutions in the global health and medical technology market,... Continue reading

Conference call today at 8:30 a.m. ET

NASHUA, N.H. – August 1, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported financial results for the three and six months ended June 30, 2019.

Second Quarter 2019 Highli... Continue reading

NASHUA, N.H. – July 29, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-months ended June 30, 2019, before the market open, and host a conference call at 8:30am Eastern Time on Thursday, August 1, 2019.

Thursday, August 1st @ 8:30am Eastern Time

Domestic:

877-407... Continue reading

Deep-learning, artificial intelligence technology assists radiologists in detecting breast cancer

Nashua, N.H. – July 11, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its advanced artificial intelligence technology and workflow solution, ProFound AI™ for 2D Mammography, re... Continue reading

iCAD’s Innovative ProFound AI™ Solution for Digital Breast Tomosynthesis offers high-performing workflow solution for radiologists

PHOENIX and NASHUA, N.H. (July 10, 2019) – SimonMed Imaging, one of the largest outpatient medical imaging providers and largest physician radiology practices in the United States, announced today their implementation of the first FDA-cleared AI program for significantly enhancing early breast cancer detection for 3D mammo... Continue reading

NASHUA, N.H. – June 18, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the JMP Securities Life Sciences Conference in New York, NY on Wednesday, June 19 at 12:00pm ET and will participate in the Piper Jaffray Heartland Summit on Thursday, June 20 in Minneapolis, MN.

About iCAD, Inc.

Headquartered in Nashua,... Continue reading

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France

Nashua, N.H. and Lille, France – June 13, 2019 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader pro... Continue reading

NASHUA, N.H. — June 13, 2019 – iCAD, Inc. (“iCAD”) (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced today the pricing of its previously announced underwritten registered public offering of 1,636,364 shares of its common stock at a price to the public of .50 per share, for gross proceeds of approximately .0 million. In addition, iCAD has granted the underwriter a 30-day option to purchase up to 245,454 additional shares of common stock to cover over-allotments, if any. The offering... Continue reading

NASHUA, N.H. — June 12, 2019 – iCAD, Inc. (“iCAD”) (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it has commenced an underwritten registered public offering of its common stock. In addition, iCAD intends to grant the underwriter a 30-day option to purchase additional shares, in a number equal to up to 15% of the number of shares of common stock sold in the offering, to cover over-allotments, if any. All shares of common stock to be sold in the proposed offering will be off... Continue reading

U.S. adoption of ProFound AI™, the Company’s deep-learning cancer detection software solution for digital breast tomosynthesis, gaining traction

Conference call today at 8:30 a.m. ET 

NASHUA, N.H. – May 7, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy... Continue reading

NASHUA, N.H. -- May 6, 2019 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today appointed R. Scott Areglado as Chief Financial Officer.  Mr. Areglado has been serving as interim Chief Financial Officer since December 2018, and previously held the role of Corporate Controller at iCAD since May 2011.

“Scott has consistently demonstrated the vision and leadership we sought for this role, and we are pleased to appoint him as Chief Fina... Continue reading

NASHUA, N.H. -- May 1, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2019, before the market open, and host a conference call at 8:30 am Eastern Time on Tuesday, May 7, 2019.

Tuesday, May 7th @ 8:30 am Eastern Time

Domestic:                 877-407-0784

International:           201-689-8560

Conference... Continue reading